II. Causes: Infection
III. Causes: Medication adverse effects
- Direct cardiotoxicity
- Dyslipidemia or Lipodystrophy
- Protease Inhibitors (especially boosted Protease Inhibitors)
- Abacavir
- Efavirenz
- Elvitegravir/Cobicistat
IV. Findings
- Common
- Coronary Artery Disease
- Longstanding HIV carries a coronary disease equivalent risk similar to Diabetes Mellitus
- HIV-Related Contributing Factors to accelerated atherogenesis
- Chronic inflammatory changes
- Virus infected Macrophages
- Endothelial dysfunction
- CD4 Count <500 is associated with an increased risk of coronary events (even if it rebounds)
- Patients with HIV also have higher rates of Tobacco Abuse and Hypertension
- Protease Inhibitors also increase dyslipidemia and Insulin Resistance
- References
- Cerebrovascular Disease
- Secondary to direct HIV neurotoxicity, opportunistic infections, Coagulopathy, chronic inflammation
- Patients with HIV also have higher rates of Tobacco Abuse, IVDA, CAD, Hypertension, CKD
- Strokes occur at younger ages in HIV patients (esp. with lower CD4 Counts, higher viral loads)
- D'Ascenzo (2015) J Cardiovasc Med 16(12):839-43 [PubMed]
- Dyslipidemia
- Obtain lipid panel and Serum Glucose at time of HIV diagnosis
- Repeat lipid panel and Glucose screening at perioidic intervals
- Protease Inhibitors provoke Hypertriglyceridemia and Low HDL
- Consider Statins if indicated (based on non-HIV Infection guidelines)
- Risk of Statin-related Drug Interactions with Protease Inhibitors, NNRTI agents
- Cardiomyopathy
- Dilated Cardiomyopathy (25% advanced HIV)
- Left Ventricular Dysfunction (21% advanced HIV)
- Myocardial fibrosis
- Present in up to 82% of HIV patients and often asymptomatic
- HIV-Related Contributing Factors
- Older Antiretroviral therapy (AZT)
- Kaposi Sarcoma
- Opportunistic Infections (Cryptococcus, Toxoplasmosis)
- Malignant infiltration (e.g. Kaposi Sarcoma, Non-Hodgkin Lymphoma, Leiomyosarcoma)
- Coronary Artery Disease
- Less common
- Myocarditis
- Pericardial Effusion
- May develop from HIV Infection or Immunocompromised state
- Opportunistic infections (e.g. Mycobacterium, HSV, CMC, Toxoplasmosis, Histoplasmosis, Cryptococcus)
- Malignancy (Kaposi Sarcoma, Lymphoma)
- Pericarditis
- Arrhythmias
- Autonomic Dysfunction
- Rare Conditions
- Endocarditis
- In addition to Bacteria (staph, strep, HACEK), fungal organisms (e.g. Candidiasis, Cryptococcus)
- Primary Pulmonary Hypertension (plexogenic pulmonary arteriopathy)
- Endocarditis
V. Symptoms
- Most are asymptomatic
VI. Signs
- Usually clinically silent
- Pericardial Effusions (usually sterile) in 25%
VII. Management
- See Cardiomyopathy
- In those with Cardiac Risk Factors, avoid agents with cardiotoxicity risk (see above)
- Tobacco Cessation
-
Hyperlipidemia Management wth Statin indicated for 10 year Cardiac Risk >5 to 7.5%
- Risk of Statin-Induced Myopathy
- Start with low dose Atorvastatin (Lipitor) 10 mg or Rosuvastatin (Crestor)
VIII. Reference
- Baloor (2018) Exam Preparatory Manual for Undergraduates Medicine, Jaypee Brothers, India, p. 242
- (2019) Presc Lett 26(8): 46
- Mathieu (April, 2000) Federal Practitioner, p. 18-20
- Swaminathan and Bafuma in Herbert (2017) EM:Rap 17(3): 2
- Chu (2017) Am Fam Physician 96(3): 161-9 [PubMed]